Ivana Božić-Antić1, Dušan Ilić1, Jelica Bjekić-Macut2, Tamara Bogavac1, Danijela Vojnović-Milutinović3, Biljana Kastratovic-Kotlica4, Nataša Milić5, Olivera Stanojlović6, Zoran Andrić2, Djuro Macut7. 1. Clinic of EndocrinologyDiabetes and Metabolic Diseases, Clinical Centre of Serbia. 2. UMC Bežanijska kosaFaculty of Medicine. 3. Institute for Biological Research "Siniša Stanković". 4. Clinic of Obstetrics and GynecologyClinical Centre of Serbia. 5. Institute of Medical Statistics. 6. Institute of Medical PhysiologyFaculty of Medicine, University of Belgrade, Belgrade, Serbia. 7. Clinic of EndocrinologyDiabetes and Metabolic Diseases, Clinical Centre of Serbia djmacut@gmail.com.
Abstract
OBJECTIVE: There are limited data on cardiometabolic risk factors and the prevalence of metabolic syndrome (MetS) across the different PCOS phenotypes in Caucasian population. Lipid accumulation product (LAP) is a clinical surrogate marker that could be used for evaluation of MetS in clinical practice. The aim of the study was to analyze metabolic characteristics and the ability of LAP to predict MetS in different PCOS phenotypes. DESIGN: Cross-sectional clinical study analyzing 365 women with PCOS divided into four phenotypes according to the ESHRE/ASRM criteria, and 125 healthy BMI-matched controls. METHODS: In all subjects, LAP was determined and MetS was diagnosed according to the National Cholesterol Education Program/Adult Treatment Panel III (NCEP-ATP III), the International Diabetes Federation (IDF) and the Joint Interim Statement (JIS) criteria. Logistic regression and ROC curve analyses were used to determine predictors of MetS in each PCOS phenotype. All analyses were performed with age and BMI adjustment. RESULTS: All PCOS phenotypes in comparison to controls had higher prevalence of MetS assessed by NCEP-ATP III criteria, and only classic phenotypes when IDF and JIS criteria were used. All phenotypes had the same prevalence of MetS irrespective of used definition. LAP and exhibited the highest diagnostic accuracy and was an independent predictor of MetS in all phenotypes. CONCLUSION: LAP is an independent and accurate clinical determinant of MetS in all PCOS phenotypes in our Caucasian population. All PCOS phenotypes, including non-classic ones, are metabolically challenged and with cardiovascular risk, particularly phenotype B.
OBJECTIVE: There are limited data on cardiometabolic risk factors and the prevalence of metabolic syndrome (MetS) across the different PCOS phenotypes in Caucasian population. Lipid accumulation product (LAP) is a clinical surrogate marker that could be used for evaluation of MetS in clinical practice. The aim of the study was to analyze metabolic characteristics and the ability of LAP to predict MetS in different PCOS phenotypes. DESIGN: Cross-sectional clinical study analyzing 365 women with PCOS divided into four phenotypes according to the ESHRE/ASRM criteria, and 125 healthy BMI-matched controls. METHODS: In all subjects, LAP was determined and MetS was diagnosed according to the National Cholesterol Education Program/Adult Treatment Panel III (NCEP-ATP III), the International Diabetes Federation (IDF) and the Joint Interim Statement (JIS) criteria. Logistic regression and ROC curve analyses were used to determine predictors of MetS in each PCOS phenotype. All analyses were performed with age and BMI adjustment. RESULTS: All PCOS phenotypes in comparison to controls had higher prevalence of MetS assessed by NCEP-ATP III criteria, and only classic phenotypes when IDF and JIS criteria were used. All phenotypes had the same prevalence of MetS irrespective of used definition. LAP and exhibited the highest diagnostic accuracy and was an independent predictor of MetS in all phenotypes. CONCLUSION: LAP is an independent and accurate clinical determinant of MetS in all PCOS phenotypes in our Caucasian population. All PCOS phenotypes, including non-classic ones, are metabolically challenged and with cardiovascular risk, particularly phenotype B.
Authors: Małgorzata Kałużna; Magdalena Czlapka-Matyasik; Pola Kompf; Jerzy Moczko; Katarzyna Wachowiak-Ochmańska; Adam Janicki; Karolina Samarzewska; Marek Ruchała; Katarzyna Ziemnicka Journal: Ther Adv Endocrinol Metab Date: 2022-01-10 Impact factor: 3.565